Literature DB >> 19012858

Part I: Liver function in oncology: biochemistry and beyond.

Kathryn M Field1, Chris Dow, Michael Michael.   

Abstract

The liver has a key role in the metabolism (ie, inactivation or activation) of many commonly used anticancer agents-cytotoxics or new biological agents. Therefore, assessment of liver function is a fundamental part of initial work-up and management of patients with cancer. An understanding of the meaning of conventional serum biochemical testing of liver function and status, what variables they are measuring, and usefulness for chemotherapy dosing is essential. Emerging awareness of the drawbacks of conventional serum biochemical testing and further understanding of the intricacies of liver function is leading to the development of alternative strategies for appropriate chemotherapy regimens and dosing. We present an overview of assessment of liver function and chemotherapy dosing. We consider the use of serum liver biochemical testing to predict liver function, potential causes of biochemical abnormalities in patients with cancer, and chemotherapy drugs that are associated with hepatotoxicity. Part II will overview the current knowledge surrounding chemotherapy dosing in the setting of liver dysfunction; as well as alternative tests of hepatic metabolic function that are beginning to be used as strategies for appropriate individualised chemotherapy administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19012858     DOI: 10.1016/S1470-2045(08)70279-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  37 in total

1.  Preliminary study on liver function changes after trisectionectomy with versus without prior portal vein embolization.

Authors:  Maciej Malinowski; Johan Friso Lock; Daniel Seehofer; Bernhard Gebauer; Antje Schulz; Lina Demirel; Jan Bednarsch; Victoria Stary; Peter Neuhaus; Martin Stockmann
Journal:  Surg Today       Date:  2015-12-31       Impact factor: 2.549

2.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

Review 3.  Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers.

Authors:  Samdeep K Mouli; Ramona Gupta; Neil Sheth; Andrew C Gordon; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

4.  Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.

Authors:  Ling Xue; Wen-Juan Zhang; Ji-Xin Tian; Lin-Na Liu; Hai-Hong Yan; Wen-Wen Zhang; Xiao-Liang Ding; Jing-Jing Zhang; Li-Yan Miao
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

5.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

6.  A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats.

Authors:  Seigo Hiratani; Ryutaro Mori; Yohei Ota; Ryusei Matsuyama; Takafumi Kumamoto; Yoji Nagashima; Daisuke Morioka; Itaru Endo
Journal:  In Vivo       Date:  2019 May-Jun       Impact factor: 2.155

Review 7.  Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function.

Authors:  Jun Gong; May Cho; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2017-04

8.  Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.

Authors:  Ricarda Rühl; Lutz Lüdemann; Anna Czarnecka; Florian Streitparth; Max Seidensticker; Konrad Mohnike; Maciej Pech; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2010-05-27       Impact factor: 3.481

9.  How I treat hepatitis C virus infection in patients with hematologic malignancies.

Authors:  Harrys A Torres; George B McDonald
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

10.  The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.

Authors:  Aaron S Mansfield; Michelle A Rudek; Diana Vulih; Gary L Smith; Pamela Jo Harris; S Percy Ivy
Journal:  Clin Cancer Res       Date:  2016-05-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.